Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
Patients having Cesarean section after they have been in labor for many hours bleed much
more, in average twice as much, as compared with patients having an elective Cesarean
section. The investigators believe a simple change in practice might contribute to reduce
this bleeding. This study will involve the use of oxytocin (also known as syntocinon),
ergonovine (also known as ergot) and carboprost (also known as hemabate). Oxytocin is
routinely used to help contract the uterus and keep it contracted after the delivery of the
baby and placenta, so as to reduce the amount of blood loss. Ergonovine is also given through
the intravenous line, while carboprost is given as an injection in the muscle. Although they
are not routinely given in every case, these are very frequently given as rescue medications
to patients who fail to respond appropriately to oxytocin. This study is designed to
determine if ergonovine or carboprost given in association with oxytocin, in a preventive
way, after delivery of the baby and placenta, can reduce the amount of blood loss during
Cesarean sections following a trial of labour.
Phase:
N/A
Details
Lead Sponsor:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital